BSNTG: Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer?

Sponsor
Fudan University (Other)
Overall Status
Recruiting
CT.gov ID
NCT03689439
Collaborator
(none)
1,000
5
47
200
4.3

Study Details

Study Description

Brief Summary

In this prospective one-arm observational study, bone scintigraphy will be performed in T1N0M0 NSCLC patients with GGO lesion and other low risk factors of bone metastasis. The occurrence rate of bone metastasis in these patients will be analyzed to evaluate the necessity of bone scintigraphy in cT1N0M0 NSCLC patients.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: bone scintigraphy

Detailed Description

Skeletal is a common metastatic site in patients with non-small cell lung cancer. The incidence of bone metastases is about 20-30% in NSCLC patients. According to the NCCN guidelines, early lung cancer patients should also undergo bone scan or PETCT before surgery to determine the presence of bone metastases. However, all of the above methods use radionuclide reagents as tracers, which pose health hazards to patients and their contacts, including medical personnel. A retrospective study conducted by our center showed that only 0.95% of patients with cT1N0M0 non-small cell lung cancer had preoperative bone metastases. In patients with early stage lung cancer whose lesions are pure ground glass nodules, the probability of developing bone metastases is zero. The low risk factors for bone metastases from this retrospective study included preoperative examination of patients with CEA <5 ng/ul and no bone-related symptoms. In patients with primary NSCLC who underwent CEA <5 ng/ul preoperatively, no bone metastases occurred; in patients with negative bone-related symptoms, the incidence of bone metastases was only 0.18%. In the case of such patients, if the bone scan is performed, not only the potential damage to the patient is increased, but also the waste of medical resources and the burden on the patient from the perspective of health economics.

Therefore, our center is expected to conduct this prospective one-arm observational clinical trial. According to the low-risk factors derived from retrospective studies, bone scintigraphy was performed in patients with GGO lesion and other low risk factors of bone metastasis, and the incidence of bone metastasis was obtained. The necessity of bone scintigraphy in cT1N0M0 NSCLC patients would be evaluated.

Study Design

Study Type:
Observational
Anticipated Enrollment :
1000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer?
Actual Study Start Date :
Dec 1, 2018
Anticipated Primary Completion Date :
Nov 1, 2021
Anticipated Study Completion Date :
Nov 1, 2022

Outcome Measures

Primary Outcome Measures

  1. The Occurrence Rate of Bone metastasis in cT1N0M0 NSCLC patients [1 month]

    The Number of cT1N0M0 NSCLC patients that had bone metastasis in this cohort

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. Patients who sign the informed consent form and are willing to complete the study according to the plan;

  2. Age 18-80 years old;

  3. ECOG score ≤ 2 points;

  4. CT shows that the main lesion is considered to be ground glass nodular lung cancer;

  5. Preoperative examination CEA <5ng/ul

  6. There are no bone related symptoms

  7. There is no obvious absolute surgical contraindication for preoperative examination.

Exclusion Criteria:
  1. History of bone related diseases.

  2. History of other kinds of cancer

Contacts and Locations

Locations

Site City State Country Postal Code
1 Anhui Chest Hospital Hefei An Hui China 230000
2 Henan Cancer Hospital Zhengzhou He Nan China 450000
3 Jiang Du People's Hospital Yangzhou Jiang Su China 225200
4 Fudan University Cancer Center Shanghai Shanghai China 200032
5 Jilin Cancer Hospital Changchun China

Sponsors and Collaborators

  • Fudan University

Investigators

  • Principal Investigator: Haiquan Chen, Ph.D, Shanghai Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Haiquan Chen, Professor, Fudan University
ClinicalTrials.gov Identifier:
NCT03689439
Other Study ID Numbers:
  • BSNTG
First Posted:
Sep 28, 2018
Last Update Posted:
Aug 18, 2020
Last Verified:
Aug 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2020